Acurx Pharmaceuticals (ACXP) Payables (2020 - 2026)
Acurx Pharmaceuticals' (ACXP) quarterly Payables came in at $2.5 million in Q1 2026, up 1.31% YoY from $2.5 million in Q1 2025, and up 4.37% on a QoQ basis from $2.4 million in Q4 2025.
Acurx Pharmaceuticals (ACXP) Payables (2020 - 2026) Analysis & Trends
Acurx Pharmaceuticals (ACXP) has 7 years of Payables data on file, last reported at $2.5 million in Q1 2026.
- Quarterly Payables rose 1.31% year-over-year to $2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.5 million (up 1.31% YoY) and the FY2025 annual result came in at $2.4 million, down 25.35% from the prior year.
- Payables advanced to $2.5 million in Q1 2026, from $2.4 million in the prior quarter.
- In the past five years, Payables ranged from a high of $3.3 million in Q3 2024 to a low of $473879.0 in Q2 2022.
- A 5-year average of $2.4 million and a median of $2.5 million in 2026 frame the typical range for Payables.
- Annual changes were most pronounced in 2022 — Payables tumbled 75.3% — and 2023, when it jumped 537.17%.
- Tracing ACXP's Payables over 5 years: stood at $2.1 million in 2022, then jumped by 47.57% to $3.0 million in 2023, then gained by 6.59% to $3.2 million in 2024, then dropped by 25.35% to $2.4 million in 2025, then gained by 4.37% to $2.5 million in 2026.
- The last three Payables figures came in at $2.5 million (Q1 2026), $2.4 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 428.93 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 35.57 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 622.65 Mn |
| 10 | Acurx Pharmaceuticals | 6.18 Mn | 6.18 Mn | - | 2.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.83 Mn |
| Mar 31, 2026 | 2.53 Mn |
| Dec 31, 2025 | 2.42 Mn |
| Sep 30, 2025 | 2.47 Mn |
| Jun 30, 2025 | 2.59 Mn |
| Mar 31, 2025 | 2.49 Mn |
| Dec 31, 2024 | 3.24 Mn |
| Sep 30, 2024 | 3.32 Mn |
| Jun 30, 2024 | 3.15 Mn |
| Mar 31, 2024 | 3.11 Mn |
| Dec 31, 2023 | 3.04 Mn |
| Sep 30, 2023 | 3.22 Mn |
| Jun 30, 2023 | 3.02 Mn |
| Mar 31, 2023 | 2.07 Mn |
| Dec 31, 2022 | 2.06 Mn |
| Sep 30, 2022 | 1.18 Mn |
| Jun 30, 2022 | 473,879.00 |
| Mar 31, 2022 | 633,028.00 |
| Dec 31, 2021 | 843,909.00 |
| Sep 30, 2021 | 712,437.00 |